The US just recently released Operation Warp Speed (OWS) for enormous COVID-19 vaccine testing with an objective to provide a vaccine by the end of this year. Operation Warp Speed plans to provide nearly 300 million reliable and safe doses of vaccine for COVID-19 by January 2021. OWS is a part of a thorough technique for fast-tracking 3 core locations advancement, production, along with circulation of COVID-19 diagnostics, therapeutics, and vaccines.
On 13 June 2020, Sinovac Biotech revealed positive initial findings from its Phase 1/2 trial of CoronaVac, COVID-19 vaccine prospect of Sinovac. CureVac started its vaccine program in early 2020.
Browse for a safe and efficient vaccine for COVID-19 is acquiring momentum. While some health care gamers are in initial stages of clinical research studies, some have actually currently exposed the time frame for late-stage trials and possible approval of their prospects.
Moderna to begin Phase 3 clinical trials for mRNA-1273 in July 2020, while AstraZeneca reinforces its production capability for AZD1222.
Sinovac Biotech will start Phase 3 medical trial quickly for CoronaVac.
BioNTech secures EUR100 million for COVID-19 vaccine production; Novavax to raise ~ US$ 200 million for COVID-19 and influenza vaccine.
INOVIO to start Phase 1/2 Clinical Trial in South Korea while CureVac acquired regulative approval from regulatory authorities in Belgium and Germany to start Phase 1 clinical research study.
COVID-19 risk still looms with nations struggling to get rid of the novel coronavirus, SARS-CoV-2. While a lot of locations are coming to grips with the first wave of infection, the ones who did end up being COVID-19-free are now facing the second wave. Globally, validated cases of COVID-19 had crossed 8.86 million including 465,740 deaths, as per WHO (as of 3:50 PM CEST, 22 June 2020).
The quest for a vaccine to fight COVID-19 has reached its pinnacle, with numerous burgeoning healthcare business joining the race to develop a efficient and safe COVID-19 vaccine. While some companies have advanced to early-stage scientific trials, some have currently announced the initiation of late-stage development and are expanding their manufacturing centers.
The United States recently released Operation Warp Speed (OWS) for tremendous COVID-19 vaccine testing with a goal to supply a vaccine by the end of this year. Operation Warp Speed intends to deliver nearly 300 million safe and reliable dosages of vaccine for COVID-19 by January 2021. OWS is a part of an extensive approach for fast-tracking 3 core locations advancement, production, in addition to distribution of COVID-19 diagnostics, vaccines, and rehabs.
In this post, we will highlight business who are in the race of developing COVID-19 vaccine:.
Moderna to Begin Phase 3 Clinical Trials of mRNA-1273 in July.
NASDAQ-listed healthcare sector player Moderna Inc (NASDAQ: MRNA) specified that the Company had finalised the Phase 3 clinical trials protocol per the feedback provided by the US FDA. Moderna highlighted that the trial is expected to register nearly 30k individuals in the United States, and it would be a randomised, placebo-controlled clinical trial.
Moreover, the Phase 3 scientific trial is forecasted to be carried out in partnership with NIAID, which belongs of the NIH (National Institutes of Health).
Stock Information: On 22 June 2020, MRNA shares closed at US$ 64.75, down by 2.41%, with a market cap of ~ US$ 24.04 billion.
AstraZeneca Bolsters Manufacturing Capacity, Moving Progressively With AZD1222.
UK-based worldwide, science-led biopharmaceutical company AstraZeneca plc (NASDAQ: AZN) divulged that AstraZeneca and Catalent Biologics signed an arrangement for production and supply of AZD1222, vaccine prospect by University of Oxford.
With this contract, Catalent will use vial filling together with product packaging capability to AstraZeneca at its Italy-based production site.
Addition to this, AZN signed a deal with Inclusive Vaccines Alliance Europe for offering Oxford Universitys vaccine, the products will start by the end of 2020 in Europe.
The University had announced Phase 2/3 study initiation in the UK in May with research studies in other geographies due to begin quickly.
Stock details: On 22 June 2020, AZN stock settled the days trade at US$ 53.42, up by 0.75%, with a market cap of nearly US$ 140.2 billion.
DO READ: Mysterious Threat of Antimicrobial Resistance Behind COVID-19.
BioNTech Secures EUR100 Million for COVID-19 Vaccine Production.
A pioneer in developing novel treatments for cancer and other extreme disorders, BioNTech SE (NASDAQ: BNTX) is developing mRNA-based vaccine BNT162 for avoiding COVID-19, in partnership with Pfizer.
On 11 June 2020, BioNTech disclosed that it had signed a financial obligation funding arrangement worth roughly EUR100 million with the European Investment Bank for the development and production of its COVID-19 vaccine program for BNT162.
With this deal, BioNTech will broaden its production capacity for providing the vaccine swiftly around the world in reaction to the ongoing chaos.
Stock Information: On 22 June 2020, BNTX ADS closed the days trade at US$ 57.45, surged by 11.86% from its previous close. The marketplace capitalisation of the stock stood at US$ 13.03 billion.
Sinovac Disclosed Positive Preliminary Results of Phase 1/2 Trial, Soon to Enter in Phase 3.
China-based leading supplier of biopharmaceutical products, Sinovac Biotech Ltd (NASDAQ: SVA) has actually developed a vaccine called as CoronaVac that utilizes an inactive novel coronavirus to create an immune action versus the active variation of the infection.
On 13 June 2020, Sinovac Biotech disclosed favorable initial findings from its Phase 1/2 trial of CoronaVac, COVID-19 vaccine prospect of Sinovac. The findings reveal favorable security as well as immunogenicity reports. In addition, SVA foresees to send a report for the Phase 2 clinical trial and a clinical study procedure for Phase 3 to NMPA China and commence the application of Phase 3 scientific trial beyond China..
According to a release dated 11 June 2020, the Company divulged its collaboration with Instituto Butantan, a research study institute in Brazil, for developing and carrying out a Phase 3 trial. Sinovac expects sharing the total information on clinical trials openly by means of academic publications.
Stock Information: SVA regular shares last estimated at US$ 6.47 on 22 June 2020, in line with the previous close, with a market capitalisation of roughly US$ 639.9 million.
Novavax to Raise US$ 200 Million to Fund COVID-19 and Flu Vaccine Studies.
A late-stage biotechnology business Novavax Inc (NASDAQ: NVAX) is establishing a vaccine, NVX-CoV2373 versus SARS-CoV-2.
Based on the announcement dated 15 June 2020, NVAX revealed that it had actually entered an arrangement to provide Convertible preferred stock (Series A), adjustable into nearly 4,388,852 shares of normal stock, to an RA capital investing fund connected within a personal positioning. The effective purchasing per share cost of typical stock for this arrangement was equivalent to the last stock cost on 12 June 2020. Especially, on finishing this arrangement, NVAX will obtain gross earnings of nearly US$ 200 million.
The increase in financial investment of Novavax, in addition to resources from CEPI and the United States Department of Defense, will provide support to the Company in developing a effective and accessible vaccine to combat COVID-19.
Stock Information: On 22 June 2020, NVAX last quoted at US$ 65.95, up by 1.85% from its last close, with a market cap of practically US$ 3.87 billion.
INOVIO to Commence Phase 1/2 Clinical Trial in South Korea.
US-based biotech gamer INOVIO Pharmaceuticals Inc (NASDAQ: INO), the Seoul National University Hospital, and IVI (the International Vaccine Institute) are operating in a collaboration to start a Phase 1/2 medical study of INO-4800 INOVIOs COVID-19 vaccine in South Korea.
This trial will evaluate the safety, tolerability, in addition to immunogenicity of vaccine candidate almost in forty healthy volunteers of 19-50 years and will broaden to enrol further 120 volunteers in the age bracket 19-64 years.
The medical trial intends to begin later on in June and is funded by the CEPI via INOVIO and is backed by the Korea Center for Disease Control (KCDC) and Korea National Institute of Health.
Stock Information: On 22 June 2020, INO last estimated at US$ 15.30, up by 7.22% from its previous close. The Company had a market cap of ~ US$ 2.41 billion.
CureVac AG to Commence Phase 1 Trial of its Vaccine Candidate for SARS-CoV-2.
A leading clinical-stage biotechnology business, CureVac AG is taken part in developing an unique category of transformative medicines based upon optimised mRNA. The Company is establishing mRNA based vaccine to hinder SARS-CoV-2, which utilizes nucleotides without any chemical adjustments in the mRNA to encode the full-length spike protein of novel coronavirus. CureVac began its vaccine program in early 2020.
On 15 June 2020, the German Federal Government exposed that it would invest EUR300 million in CureVac through the KfW group.
On 17 June 2020, CureVac divulged that it had actually gotten approval from regulatory authorities of Belgium and Germany to start Phase 1 medical research study of its mRNA based vaccine candidate. The trial will begin swiftly and will be performed in Belgium and Germany.